JP2021502988A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502988A5 JP2021502988A5 JP2020526547A JP2020526547A JP2021502988A5 JP 2021502988 A5 JP2021502988 A5 JP 2021502988A5 JP 2020526547 A JP2020526547 A JP 2020526547A JP 2020526547 A JP2020526547 A JP 2020526547A JP 2021502988 A5 JP2021502988 A5 JP 2021502988A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- optionally
- antigen
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 28
- 102000036639 antigens Human genes 0.000 claims 28
- 108091007433 antigens Proteins 0.000 claims 28
- -1 imidazole pyrimidine compound Chemical class 0.000 claims 23
- 239000000203 mixture Substances 0.000 claims 14
- 239000002671 adjuvant Substances 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 229960005486 vaccine Drugs 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 102000002689 Toll-like receptor Human genes 0.000 claims 6
- 108020000411 Toll-like receptor Proteins 0.000 claims 6
- 229940037003 alum Drugs 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000004452 carbocyclyl group Chemical group 0.000 claims 5
- 230000028993 immune response Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 102000007863 pattern recognition receptors Human genes 0.000 claims 5
- 108010089193 pattern recognition receptors Proteins 0.000 claims 5
- 241000700605 Viruses Species 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 241000894006 Bacteria Species 0.000 claims 3
- 102000003930 C-Type Lectins Human genes 0.000 claims 3
- 108090000342 C-Type Lectins Proteins 0.000 claims 3
- 208000035473 Communicable disease Diseases 0.000 claims 3
- 241000233866 Fungi Species 0.000 claims 3
- 102000012064 NLR Proteins Human genes 0.000 claims 3
- 108091005686 NOD-like receptors Proteins 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 244000045947 parasite Species 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 102000029797 Prion Human genes 0.000 claims 2
- 108091000054 Prion Proteins 0.000 claims 2
- 108091005685 RIG-I-like receptors Proteins 0.000 claims 2
- 241000607626 Vibrio cholerae Species 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 239000002158 endotoxin Substances 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims 2
- 244000000010 microbial pathogen Species 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000000770 proinflammatory effect Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 241001529453 unidentified herpesvirus Species 0.000 claims 2
- 229940118696 vibrio cholerae Drugs 0.000 claims 2
- 241000228212 Aspergillus Species 0.000 claims 1
- 241000304886 Bacilli Species 0.000 claims 1
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- 241000193738 Bacillus anthracis Species 0.000 claims 1
- 241000228405 Blastomyces dermatitidis Species 0.000 claims 1
- 241000588832 Bordetella pertussis Species 0.000 claims 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims 1
- 241000193449 Clostridium tetani Species 0.000 claims 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 claims 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 208000010772 Dog disease Diseases 0.000 claims 1
- 241001115402 Ebolavirus Species 0.000 claims 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims 1
- 241000709661 Enterovirus Species 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 241000606768 Haemophilus influenzae Species 0.000 claims 1
- 108010034145 Helminth Proteins Proteins 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 241000709721 Hepatovirus A Species 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 241000228404 Histoplasma capsulatum Species 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 201000005807 Japanese encephalitis Diseases 0.000 claims 1
- 241000710842 Japanese encephalitis virus Species 0.000 claims 1
- 241000222722 Leishmania <genus> Species 0.000 claims 1
- 201000005505 Measles Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000005647 Mumps Diseases 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 1
- 241000702670 Rotavirus Species 0.000 claims 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 241001149963 Sporothrix schenckii Species 0.000 claims 1
- 241000295644 Staphylococcaceae Species 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 208000037063 Thinness Diseases 0.000 claims 1
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 claims 1
- 108010060752 Toll-Like Receptor 8 Proteins 0.000 claims 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims 1
- 208000003152 Yellow Fever Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 229940031567 attenuated vaccine Drugs 0.000 claims 1
- 229940065181 bacillus anthracis Drugs 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 229940047650 haemophilus influenzae Drugs 0.000 claims 1
- 244000000013 helminth Species 0.000 claims 1
- 230000015788 innate immune response Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 208000018773 low birth weight Diseases 0.000 claims 1
- 231100000533 low birth weight Toxicity 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 208000010805 mumps infectious disease Diseases 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 229940031626 subunit vaccine Drugs 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 206010048828 underweight Diseases 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023131871A JP2023175686A (ja) | 2017-11-14 | 2023-08-14 | ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762586137P | 2017-11-14 | 2017-11-14 | |
| US62/586,137 | 2017-11-14 | ||
| PCT/US2018/061135 WO2019099578A1 (en) | 2017-11-14 | 2018-11-14 | Use of imidazopyrimidine for modulating human immune response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023131871A Division JP2023175686A (ja) | 2017-11-14 | 2023-08-14 | ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502988A JP2021502988A (ja) | 2021-02-04 |
| JP2021502988A5 true JP2021502988A5 (https=) | 2021-12-23 |
| JP7382316B2 JP7382316B2 (ja) | 2023-11-16 |
Family
ID=66539100
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526547A Active JP7382316B2 (ja) | 2017-11-14 | 2018-11-14 | ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用 |
| JP2023131871A Pending JP2023175686A (ja) | 2017-11-14 | 2023-08-14 | ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023131871A Pending JP2023175686A (ja) | 2017-11-14 | 2023-08-14 | ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11730810B2 (https=) |
| EP (1) | EP3710007A4 (https=) |
| JP (2) | JP7382316B2 (https=) |
| KR (2) | KR102775718B1 (https=) |
| CN (1) | CN111587114A (https=) |
| WO (1) | WO2019099578A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7304855B2 (ja) | 2017-11-14 | 2023-07-07 | ザ チルドレンズ メディカル センター コーポレーション | 新規イミダゾピリミジン化合物およびそれらの使用 |
| CN111587114A (zh) * | 2017-11-14 | 2020-08-25 | 儿童医学中心公司 | 用于调节人免疫应答的咪唑并嘧啶的用途 |
| EP4277650A4 (en) * | 2021-01-15 | 2025-05-14 | The Board of Trustees of the Leland Stanford Junior University | Adjuvants to stimulate broad and persistent innate immunity against various antigens |
| WO2024151501A1 (en) * | 2023-01-09 | 2024-07-18 | The Children's Medical Center Corporation | Novel imidazopyrimidine compound and uses thereof |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69524598T2 (de) | 1994-06-20 | 2002-07-11 | Takeda Chemical Industries, Ltd. | Kondensierte imidazolderivate, ihre herstellung und verwendung |
| DE60018037T2 (de) | 1999-11-10 | 2006-01-12 | Ortho-Mcneil Pharmaceutical, Inc. | Substituierte 2-aryl-3-(heteroaryl)-imidazo[1,2-alpha]pyrimidine und ihren verwandten arzneimittel und verfahren |
| JP2001302667A (ja) | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| EP1294723A1 (en) | 2000-05-24 | 2003-03-26 | MERCK SHARP & DOHME LTD. | 3-phenyl-imidazo-pyrimidine derivatives as ligands for gaba receptors |
| GB0128499D0 (en) * | 2001-11-28 | 2002-01-23 | Merck Sharp & Dohme | Therapeutic agents |
| EP1737459B1 (en) | 2004-03-19 | 2009-08-05 | Warner-Lambert Company LLC | Imidazopyridine and imidazopyrimidine derivatives as antibacterial agents |
| BRPI0513811A (pt) | 2004-07-27 | 2008-07-15 | Gilead Sciences Inc | imidazo [4,5-d] pirimidinas, seus usos e processos de preparação |
| WO2006029223A2 (en) * | 2004-09-08 | 2006-03-16 | Children's Medical Center Corporation | Method for stimulating the immune response of newborns |
| EP1910385B1 (en) | 2005-08-04 | 2013-07-24 | Sirtris Pharmaceuticals, Inc. | Benzothiazoles and thiazolopyridines as sirtuin modulators |
| US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| EP1955077B1 (en) * | 2005-12-02 | 2012-06-13 | Sirtris Pharmaceuticals, Inc. | Mass spectrometry assays for acetyltransferase/deacetylase activity |
| WO2008027812A2 (en) | 2006-08-28 | 2008-03-06 | Forest Laboratories Holdings Limited | Imidazopyridine and imidazopyrimidine derivatives |
| ME02372B (me) | 2006-11-22 | 2016-06-20 | Incyte Holdings Corp | Imidazotriazini i imidazopiramidini kao inhibitori kinaze |
| RU2364597C1 (ru) | 2007-12-14 | 2009-08-20 | Андрей Александрович Иващенко | ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ |
| EP2103614A1 (en) | 2008-03-18 | 2009-09-23 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as melanocortin-4 receptor modulators |
| US20100168084A1 (en) | 2008-05-08 | 2010-07-01 | Huber L Julie | Therapeutic compounds and related methods of use |
| FR2933982A1 (fr) | 2008-07-18 | 2010-01-22 | Sanofi Aventis | Nouveaux derives imidazo°1,2-a!pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| US8962652B2 (en) * | 2009-10-22 | 2015-02-24 | Gilead Sciences, Inc. | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
| TWI617559B (zh) | 2010-12-22 | 2018-03-11 | 江蘇恆瑞醫藥股份有限公司 | ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物 |
| GB201120000D0 (en) | 2011-11-20 | 2012-01-04 | Glaxosmithkline Biolog Sa | Vaccine |
| CN103570625A (zh) | 2012-07-19 | 2014-02-12 | 南京英派药业有限公司 | N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用 |
| PL2931738T3 (pl) | 2012-12-13 | 2019-07-31 | Aduro Biotech, Inc. | Kompozycje zawierające cykliczne dinukleotydy purynowe o zdefiniowanej stereochemii i sposoby ich otrzymywania i zastosowania |
| EP2958889B1 (en) | 2013-02-25 | 2017-03-22 | The Scripps Research Institute | Neoseptins: small molecule adjuvants |
| AU2014224976B2 (en) * | 2013-03-05 | 2017-09-28 | Merck Patent Gmbh | 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents |
| US9296754B2 (en) * | 2013-03-15 | 2016-03-29 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| UY35400A (es) * | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
| US9186361B2 (en) | 2013-03-15 | 2015-11-17 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| CN103467590B (zh) * | 2013-09-02 | 2016-04-13 | 深圳大学 | 生物偶联体、制备其的嘌呤类化合物、合成方法、药用制剂以及其在免疫调节中的应用 |
| GB201321736D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| US10821175B2 (en) * | 2014-02-25 | 2020-11-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| RU2725979C2 (ru) | 2014-06-25 | 2020-07-08 | Ф. Хоффманн-Ля Рош Аг | ИМИДАЗО[1,2-а]ПИРАЗИН-1-ИЛ-БЕНЗАМИДЫ ДЛЯ ЛЕЧЕНИЯ СПИНАЛЬНОЙ МЫШЕЧНОЙ АТРОФИИ |
| WO2016148114A1 (ja) | 2015-03-13 | 2016-09-22 | 国立大学法人北海道大学 | 酸化ストレス誘導神経細胞死抑制化合物 |
| TWI704154B (zh) * | 2015-12-03 | 2020-09-11 | 英商葛蘭素史克智慧財產發展有限公司 | 新穎化合物 |
| CN111587114A (zh) * | 2017-11-14 | 2020-08-25 | 儿童医学中心公司 | 用于调节人免疫应答的咪唑并嘧啶的用途 |
| JP7304855B2 (ja) * | 2017-11-14 | 2023-07-07 | ザ チルドレンズ メディカル センター コーポレーション | 新規イミダゾピリミジン化合物およびそれらの使用 |
-
2018
- 2018-11-14 CN CN201880086316.3A patent/CN111587114A/zh active Pending
- 2018-11-14 EP EP18878690.9A patent/EP3710007A4/en active Pending
- 2018-11-14 KR KR1020207016958A patent/KR102775718B1/ko active Active
- 2018-11-14 KR KR1020257006482A patent/KR20250030535A/ko active Pending
- 2018-11-14 US US16/763,847 patent/US11730810B2/en active Active
- 2018-11-14 WO PCT/US2018/061135 patent/WO2019099578A1/en not_active Ceased
- 2018-11-14 JP JP2020526547A patent/JP7382316B2/ja active Active
-
2023
- 2023-08-14 JP JP2023131871A patent/JP2023175686A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502988A5 (https=) | ||
| Sun et al. | Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2 | |
| Maes et al. | Hantaviruses: immunology, treatment, and prevention | |
| Peebles Jr et al. | Pathogenesis of respiratory syncytial virus infection in the murine model | |
| Takaki et al. | Toll-like receptor 3 in nasal CD103+ dendritic cells is involved in immunoglobulin A production | |
| US10052378B2 (en) | Pharmaceutical compositions comprising CpG oligonucleotides | |
| Purushotham et al. | Vaccine platforms for the prevention of Lassa fever | |
| Chuai et al. | Poly (I: C)/alum mixed adjuvant priming enhances HBV subunit vaccine-induced immunity in mice when combined with recombinant adenoviral-based HBV vaccine boosting | |
| Ebensen et al. | The combination vaccine adjuvant system alum/c-di-AMP results in quantitative and qualitative enhanced immune responses post immunization | |
| Valkenburg et al. | Immunity to seasonal and pandemic influenza A viruses | |
| Hillaire et al. | Clearance of influenza virus infections by T cells: risk of collateral damage? | |
| Campos et al. | The effectiveness and limitations of immune memory: understanding protective immune responses | |
| JP2019163286A (ja) | Ｂ型肝炎ウイルスコアタンパク質および表面抗原タンパク質をコードする核酸分子ならびにそれを含むワクチン | |
| JP2017507911A5 (https=) | ||
| JP2017178890A (ja) | 自然免疫を活性化する粘膜ワクチン用アジュバント | |
| Kim et al. | Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity | |
| Wu et al. | A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis | |
| Du et al. | The adjuvant effects of co‐stimulatory molecules on cellular and memory responses to HBsAg DNA vaccination | |
| Bot et al. | Molecular and cellular control of T1/T2 immunity at the interface between antimicrobial defense and immune pathology | |
| Yao et al. | Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity | |
| Le et al. | Adjuvant effects of combination monophosphoryl lipid A and poly I: C on antigen-specific immune responses and protective efficacy of influenza vaccines | |
| Martin et al. | Influence of time and number of antigen encounters on memory CD8 T cell development | |
| Takeda et al. | Vaccine adjuvant ARNAX promotes mucosal IgA production in influenza HA vaccination | |
| JPWO2019211294A5 (https=) | ||
| US20190125860A1 (en) | Equine Influenza Virus Live Attenuated Vaccines |